首页LSTA • NASDAQ
add
Lisata Therapeutics Inc
昨日收盘价
$2.68
当日价格范围
$2.69 - $2.75
年度波幅
$1.87 - $4.20
市值
2312.92万 USD
平均交易量
1.31万
市盈率
-
股息率
-
主要交易所
NASDAQ
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 584.70万 | -11.42% |
净收入 | -472.40万 | 12.53% |
净利润率 | — | — |
每股收益 | -0.55 | 15.38% |
息税折旧摊销前利润 | -580.40万 | 11.46% |
有效税率 | 16.92% | — |
资产负债表
总资产
负债总额
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 2583.30万 | -40.41% |
总资产 | 2898.10万 | -39.92% |
负债总额 | 387.90万 | -29.43% |
权益总额 | 2510.20万 | — |
发行在外的股份 | 859.82万 | — |
市净率 | 0.91 | — |
资产回报率 | -45.69% | — |
资本回报率 | -53.50% | — |
现金流
现金净变动
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
净收入 | -472.40万 | 12.53% |
来自运营的现金 | -540.20万 | 23.13% |
投资现金 | 943.10万 | 46.54% |
融资现金 | -2.30万 | 83.80% |
现金净变动 | 400.80万 | 608.63% |
自由现金流 | -432.14万 | 24.29% |
简介
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
成立时间
1980
员工数量
26
